Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib with or without prophylactic rivaroxaban in EGFR-mutated NSCLC: VTE incidence
ChiCTR2600119885Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of befotertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Incidence of venous thromboembolism (VTE). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600119885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119885.